Clinical Pathology - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 10 of 15
  • Item
    Thumbnail Image
    Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci
    Tanskanen, T ; van den Berg, L ; Valimaki, N ; Aavikko, M ; Ness-Jensen, E ; Hveem, K ; Wettergren, Y ; Lindskog, EB ; Tonisson, N ; Metspalu, A ; Silander, K ; Orlando, G ; Law, PJ ; Tuupanen, S ; Gylfe, AE ; Hanninen, UA ; Cajuso, T ; Kondelin, J ; Sarin, A-P ; Pukkala, E ; Jousilahti, P ; Salomaa, V ; Ripatti, S ; Palotie, A ; Jarvinen, H ; Renkonen-Sinisalo, L ; Lepisto, A ; Bohm, J ; Mecklin, J-P ; Al-Tassan, NA ; Palles, C ; Martin, L ; Barclay, E ; Tenesa, A ; Farrington, SM ; Timofeeva, MN ; Meyer, BF ; Wakil, SM ; Campbell, H ; Smith, CG ; Idziaszczyk, S ; Maughan, TS ; Kaplan, R ; Kerr, R ; Kerr, D ; Buchanan, DD ; Win, AK ; Hopper, J ; Jenkins, MA ; Newcomb, PA ; Gallinger, S ; Conti, D ; Schumacher, FR ; Casey, G ; Cheadle, JP ; Dunlop, MG ; Tomlinson, IP ; Houlston, RS ; Palin, K ; Aaltonen, LA (WILEY, 2018-02-01)
    Genome-wide association studies have been successful in elucidating the genetic basis of colorectal cancer (CRC), but there remains unexplained variability in genetic risk. To identify new risk variants and to confirm reported associations, we conducted a genome-wide association study in 1,701 CRC cases and 14,082 cancer-free controls from the Finnish population. A total of 9,068,015 genetic variants were imputed and tested, and 30 promising variants were studied in additional 11,647 cases and 12,356 controls of European ancestry. The previously reported association between the single-nucleotide polymorphism (SNP) rs992157 (2q35) and CRC was independently replicated (p = 2.08 × 10-4 ; OR, 1.14; 95% CI, 1.06-1.23), and it was genome-wide significant in combined analysis (p = 1.50 × 10-9 ; OR, 1.12; 95% CI, 1.08-1.16). Variants at 2q35, 6p21.2, 8q23.3, 8q24.21, 10q22.3, 10q24.2, 11q13.4, 11q23.1, 14q22.2, 15q13.3, 18q21.1, 20p12.3 and 20q13.33 were associated with CRC in the Finnish population (false discovery rate < 0.1), but new risk loci were not found. These results replicate the effects of multiple loci on the risk of CRC and identify shared risk alleles between the Finnish population isolate and outbred populations.
  • Item
    Thumbnail Image
    Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer
    Rodriguez-Broadbent, H ; Law, PJ ; Sud, A ; Palin, K ; Tuupanen, S ; Gylfe, A ; Hanninen, UA ; Cajuso, T ; Tanskanen, T ; Kondelin, J ; Kaasinen, E ; Sarin, A-P ; Ripatti, S ; Eriksson, JG ; Rissanen, H ; Knekt, P ; Pukkala, E ; Jousilahti, P ; Salomaa, V ; Palotie, A ; Renkonen-Sinisalo, L ; Lepisto, A ; Bohm, J ; Mecklin, J-P ; Al-Tassan, NA ; Palles, C ; Martin, L ; Barclay, E ; Farrington, SM ; Timofeeva, MN ; Meyer, BF ; Wakil, SM ; Campbell, H ; Smith, CG ; Idziaszczyk, S ; Maughan, TS ; Kaplan, R ; Kerr, R ; Kerr, D ; Passarelli, MN ; Figueiredo, JC ; Buchanan, DD ; Win, AK ; Hopper, JL ; Jenkins, MA ; Lindor, NM ; Newcomb, PA ; Gallinger, S ; Conti, D ; Schumacher, F ; Casey, G ; Aaltonen, LA ; Cheadle, JP ; Tomlinson, IP ; Dunlop, MG ; Houlston, RS (WILEY, 2017-06-15)
    While elevated blood cholesterol has been associated with an increased risk of colorectal cancer (CRC) in observational studies, causality is uncertain. Here we apply a Mendelian randomisation (MR) analysis to examine the potential causal relationship between lipid traits and CRC risk. We used single nucleotide polymorphisms (SNPs) associated with blood levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) as instrumental variables (IV). We calculated MR estimates for each risk factor with CRC using SNP-CRC associations from 9,254 cases and 18,386 controls. Genetically predicted higher TC was associated with an elevated risk of CRC (odds ratios (OR) per unit SD increase = 1.46, 95% confidence interval [CI]: 1.20-1.79, p = 1.68 × 10-4 ). The pooled ORs for LDL, HDL, and TG were 1.05 (95% CI: 0.92-1.18, p = 0.49), 0.94 (95% CI: 0.84-1.05, p = 0.27), and 0.98 (95% CI: 0.85-1.12, p = 0.75) respectively. A genetic risk score for 3-hydoxy-3-methylglutaryl-coenzyme A reductase (HMGCR) to mimic the effects of statin therapy was associated with a reduced CRC risk (OR = 0.69, 95% CI: 0.49-0.99, p = 0.046). This study supports a causal relationship between higher levels of TC with CRC risk, and a further rationale for implementing public health strategies to reduce the prevalence of hyperlipidaemia.
  • Item
    Thumbnail Image
    Physical activity and the risk of colorectal cancer in Lynch syndrome
    Dashti, SG ; Win, AK ; Hardikar, SS ; Glombicki, SE ; Mallenahalli, S ; Thirumurthi, S ; Peterson, SK ; You, YN ; Buchanan, DD ; Figueiredo, JC ; Campbell, PT ; Gallinger, S ; Newcomb, PA ; Potter, JD ; Lindor, NM ; Le Marchand, L ; Haile, RW ; Hopper, JL ; Jenkins, MA ; Basen-Engquist, KM ; Lynch, PM ; Pande, M (WILEY, 2018-11-01)
    Greater physical activity is associated with a decrease in risk of colorectal cancer for the general population; however, little is known about its relationship with colorectal cancer risk in people with Lynch syndrome, carriers of inherited pathogenic mutations in genes affecting DNA mismatch repair (MMR). We studied a cohort of 2,042 MMR gene mutations carriers (n = 807, diagnosed with colorectal cancer), from the Colon Cancer Family Registry. Self-reported physical activity in three age-periods (20-29, 30-49 and ≥50 years) was summarized as average metabolic equivalent of task hours per week (MET-hr/week) during the age-period of cancer diagnosis or censoring (near-term exposure) and across all age-periods preceding cancer diagnosis or censoring (long-term exposure). Weighted Cox regression was used to estimate the hazard ratio (HR) and 95% confidence intervals (CI) for the association between physical activity and colorectal cancer risk. Near-term physical activity was associated with a small reduction in the risk of colorectal cancer (HR ≥35 vs. <3.5 MET-hr/week, 0.71; 95% CI, 0.53-0.96). The strength and direction of associations were similar for long-term physical activity, although the associations were not nominally significant. Our results suggest that physical activity is inversely associated with the risk of colorectal cancer for people with Lynch syndrome; however, further confirmation is warranted. The potential modifying effect of physical activity on colorectal cancer risk in people with Lynch syndrome could be useful for risk prediction and support counseling advice for lifestyle modification to reduce cancer risk.
  • Item
    Thumbnail Image
    Type 2 diabetes mellitus, blood cholesterol, triglyceride and colorectal cancer risk in Lynch syndrome
    Dashti, SG ; Li, WY ; Buchanan, DD ; Clendenning, M ; Rosty, C ; Winship, IM ; Macrae, FA ; Giles, GG ; Hardikar, S ; Hua, X ; Thibodeau, SN ; Figueiredo, JC ; Casey, G ; Haile, RW ; Gallinger, S ; Le Marchand, L ; Newcomb, PA ; Potter, JD ; Lindor, NM ; Hopper, JL ; Jenkins, MA ; Win, AK (NATURE PUBLISHING GROUP, 2019-11-12)
    BACKGROUND: Type 2 diabetes mellitus and high total cholesterol and triglycerides are known to be associated with increased colorectal cancer risk for the general population. These associations are unknown for people with a germline DNA mismatch repair gene mutation (Lynch syndrome), who are at high risk of colorectal cancer. METHODS: This study included 2023 (56.4% female) carriers with a mismatch repair gene mutation (737 in MLH1, 928 in MSH2, 230 in MSH6, 106 in PMS2, 22 in EPCAM) recruited by the Colon Cancer Family Registry between 1998 and 2012. Weighted Cox regression was used to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for the associations between self-reported type 2 diabetes, high cholesterol, triglyceride and colorectal cancer risk. RESULTS: Overall, 802 carriers were diagnosed with colorectal cancer at a median age of 42 years. A higher risk of colorectal cancer was observed in those with self-reported type-2 diabetes (HR 1.92; 95% CI, 1.03-3.58) and high cholesterol (HR 1.76; CI 1.23-2.52) compared with those without these conditions. There was no evidence of high triglyceride being associated with colorectal cancer risk. CONCLUSION: For people with Lynch syndrome, self-reported type-2 diabetes mellitus and high cholesterol were associated with increased colorectal cancer risk.
  • Item
    No Preview Available
    Cancer Risks for PMS2-Associated Lynch Syndrome
    ten Broeke, SW ; van der Klift, HM ; Tops, CMJ ; Aretz, S ; Bernstein, I ; Buchanan, DD ; de la Chapelle, A ; Capella, G ; Clendenning, M ; Engel, C ; Gallinger, S ; Gomez Garcia, E ; Figueiredo, JC ; Haile, R ; Hampel, HL ; Hopper, JL ; Hoogerbrugge, N ; Doeberitz, MVK ; Le Marchand, L ; Letteboer, TGW ; Jenkins, MA ; Lindblom, A ; Lindor, NM ; Mensenkamp, AR ; Moller, P ; Newcomb, PA ; van Os, TAM ; Pearlman, R ; Pineda, M ; Rahner, N ; Redeker, EJW ; Olderode-Berends, MJW ; Rosty, C ; Schackert, HK ; Scott, R ; Senter, L ; Spruijt, L ; Steinke-Lange, V ; Suerink, M ; Thibodeau, S ; Vos, YJ ; Wagner, A ; Winship, I ; Hes, FJ ; Vasen, HFA ; Wijnen, JT ; Nielsen, M ; Win, AK (AMER SOC CLINICAL ONCOLOGY, 2018-10-10)
    PURPOSE: Lynch syndrome due to pathogenic variants in the DNA mismatch repair genes MLH1, MSH2, and MSH6 is predominantly associated with colorectal and endometrial cancer, although extracolonic cancers have been described within the Lynch tumor spectrum. However, the age-specific cumulative risk (penetrance) of these cancers is still poorly defined for PMS2-associated Lynch syndrome. Using a large data set from a worldwide collaboration, our aim was to determine accurate penetrance measures of cancers for carriers of heterozygous pathogenic PMS2 variants. METHODS: A modified segregation analysis was conducted that incorporated both genotyped and nongenotyped relatives, with conditioning for ascertainment to estimates corrected for bias. Hazard ratios (HRs) and corresponding 95% CIs were estimated for each cancer site for mutation carriers compared with the general population, followed by estimation of penetrance. RESULTS: In total, 284 families consisting of 4,878 first- and second-degree family members were included in the analysis. PMS2 mutation carriers were at increased risk for colorectal cancer (cumulative risk to age 80 years of 13% [95% CI, 7.9% to 22%] for males and 12% [95% CI, 6.7% to 21%] for females) and endometrial cancer (13% [95% CI, 7.0%-24%]), compared with the general population (6.6%, 4.7%, and 2.4%, respectively). There was no clear evidence of an increased risk of ovarian, gastric, hepatobiliary, bladder, renal, brain, breast, prostate, or small bowel cancer. CONCLUSION: Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial cancer but not for any other Lynch syndrome-associated cancer. This finding justifies that PMS2-specific screening protocols could be restricted to colonoscopies. The role of risk-reducing hysterectomy and bilateral salpingo-oophorectomy for PMS2 mutation carriers needs further discussion.
  • Item
    No Preview Available
    Novel Common Genetic Susceptibility Loci for Colorectal Cancer
    Schmit, SL ; Edlund, CK ; Schumacher, FR ; Gong, J ; Harrison, TA ; Huyghe, JR ; Qu, C ; Melas, M ; Van den Berg, DJ ; Wang, H ; Tring, S ; Plummer, SJ ; Albanes, D ; Alonso, MH ; Amos, CI ; Anton, K ; Aragaki, AK ; Arndt, V ; Barry, EL ; Berndt, SI ; Bezieau, S ; Bien, S ; Bloomer, A ; Boehm, J ; Boutron-Ruault, M-C ; Brenner, H ; Brezina, S ; Buchanan, DD ; Butterbach, K ; Caan, BJ ; Campbell, PT ; Carlson, CS ; Castelao, JE ; Chan, AT ; Chang-Claude, J ; Chanock, SJ ; Cheng, I ; Cheng, Y-W ; Chin, LS ; Church, JM ; Church, T ; Coetzee, GA ; Cotterchio, M ; Correa, MC ; Curtis, KR ; Duggan, D ; Easton, DF ; English, D ; Feskens, EJM ; Fischer, R ; FitzGerald, LM ; Fortini, BK ; Fritsche, LG ; Fuchs, CS ; Gago-Dominguez, M ; Gala, M ; Gallinger, SJ ; Gauderman, WJ ; Giles, GG ; Giovannucci, EL ; Gogarten, SM ; Gonzalez-Villalpando, C ; Gonzalez-Villalpando, EM ; Grady, WM ; Greenson, JK ; Gsur, A ; Gunter, M ; Haiman, CA ; Hampe, J ; Harlid, S ; Harju, JF ; Hayes, RB ; Hofer, P ; Hoffmeister, M ; Hopper, JL ; Huang, S-C ; Huerta, JM ; Hudson, TJ ; Hunter, DJ ; Idos, GE ; Iwasaki, M ; Jackson, RD ; Jacobs, EJ ; Jee, SH ; Jenkins, MA ; Jia, W-H ; Jiao, S ; Joshi, AD ; Kolonel, LN ; Kono, S ; Kooperberg, C ; Krogh, V ; Kuehn, T ; Kury, S ; LaCroix, A ; Laurie, CA ; Lejbkowicz, F ; Lemire, M ; Lenz, H-J ; Levine, D ; Li, CI ; Li, L ; Lieb, W ; Lin, Y ; Lindor, NM ; Liu, Y-R ; Loupakis, F ; Lu, Y ; Luh, F ; Ma, J ; Mancao, C ; Manion, FJ ; Markowitz, SD ; Martin, V ; Matsuda, K ; Matsuo, K ; McDonnell, KJ ; McNeil, CE ; Milne, R ; Molina, AJ ; Mukherjee, B ; Murphy, N ; Newcomb, PA ; Offit, K ; Omichessan, H ; Palli, D ; Cotore, JPP ; Perez-Mayoral, J ; Pharoah, PD ; Potter, JD ; Qu, C ; Raskin, L ; Rennert, G ; Rennert, HS ; Riggs, BM ; Schafmayer, C ; Schoen, RE ; Sellers, TA ; Seminara, D ; Severi, G ; Shi, W ; Shibata, D ; Shu, X-O ; Siegel, EM ; Slattery, ML ; Southey, M ; Stadler, ZK ; Stern, MC ; Stintzing, S ; Taverna, D ; Thibodeau, SN ; Thomas, DC ; Trichopoulou, A ; Tsugane, S ; Ulrich, CM ; van Duijnhoven, FJB ; van Guelpan, B ; Vijai, J ; Virtamo, J ; Weinstein, SJ ; White, E ; Win, AK ; Wolk, A ; Woods, M ; Wu, AH ; Wu, K ; Xiang, Y-B ; Yen, Y ; Zanke, BW ; Zeng, Y-X ; Zhang, B ; Zubair, N ; Kweon, S-S ; Figueiredo, JC ; Zheng, W ; Le Marchand, L ; Lindblom, A ; Moreno, V ; Peters, U ; Casey, G ; Hsu, L ; Conti, DV ; Gruber, SB (OXFORD UNIV PRESS INC, 2019-02)
    BACKGROUND: Previous genome-wide association studies (GWAS) have identified 42 loci (P < 5 × 10-8) associated with risk of colorectal cancer (CRC). Expanded consortium efforts facilitating the discovery of additional susceptibility loci may capture unexplained familial risk. METHODS: We conducted a GWAS in European descent CRC cases and control subjects using a discovery-replication design, followed by examination of novel findings in a multiethnic sample (cumulative n = 163 315). In the discovery stage (36 948 case subjects/30 864 control subjects), we identified genetic variants with a minor allele frequency of 1% or greater associated with risk of CRC using logistic regression followed by a fixed-effects inverse variance weighted meta-analysis. All novel independent variants reaching genome-wide statistical significance (two-sided P < 5 × 10-8) were tested for replication in separate European ancestry samples (12 952 case subjects/48 383 control subjects). Next, we examined the generalizability of discovered variants in East Asians, African Americans, and Hispanics (12 085 case subjects/22 083 control subjects). Finally, we examined the contributions of novel risk variants to familial relative risk and examined the prediction capabilities of a polygenic risk score. All statistical tests were two-sided. RESULTS: The discovery GWAS identified 11 variants associated with CRC at P < 5 × 10-8, of which nine (at 4q22.2/5p15.33/5p13.1/6p21.31/6p12.1/10q11.23/12q24.21/16q24.1/20q13.13) independently replicated at a P value of less than .05. Multiethnic follow-up supported the generalizability of discovery findings. These results demonstrated a 14.7% increase in familial relative risk explained by common risk alleles from 10.3% (95% confidence interval [CI] = 7.9% to 13.7%; known variants) to 11.9% (95% CI = 9.2% to 15.5%; known and novel variants). A polygenic risk score identified 4.3% of the population at an odds ratio for developing CRC of at least 2.0. CONCLUSIONS: This study provides insight into the architecture of common genetic variation contributing to CRC etiology and improves risk prediction for individualized screening.
  • Item
    No Preview Available
    Risks of Colorectal Cancer and Cancer-Related Mortality in Familial Colorectal Cancer Type X and Lynch Syndrome Families
    Choi, Y-H ; Lakhal-Chaieb, L ; Krol, A ; Yu, B ; Buchanan, D ; Ahnen, D ; Le Marchand, L ; Newcomb, PA ; Win, AK ; Jenkins, M ; Lindor, NM ; Briollais, L (OXFORD UNIV PRESS INC, 2019-07)
    BACKGROUND: The risk of cancers is well characterized in Lynch syndrome (LS) families but has been less studied in familial colorectal cancer type X (FCCTX) families. METHODS: In this article, we compare the risk estimates of first and second colorectal cancers (CRCs) in 168 FCTTX and 780 LS families recruited through the Colon Cancer Family Registry as well as the risk of cancer-related deaths and disease-free survival (DFS) after a first CRC. Our methodology is based on a survival analysis approach, developed specifically to model the occurrence of successive cancers (ie, first and second CRCs) in the presence of competing risk events (ie, death from any causes). RESULTS: We found an excess risk of first and second CRC in individuals with LS compared to FCCTX family members. However, for an average age at first CRC of 60 years in FCCTX families and 50 years in LS families, the DFS rates were comparable in men but lower in women from FCCTX vs LS families, eg , 75.1% (95% confidence interval [CI] = 69.0% to 80.9%) vs 78.9% (95% CI = 76.3% to 81.3%) for the 10-year DFS. The 10-year risk of cancer-related death was higher in FCCTX families vs LS families, eg, 15.4% in men (95% CI = 10.9% to 19.8%) and 19.3% in women (95% CI = 13.6% to 24.7%) vs 8.9% (95% CI = 7.5% to 11.4%) and 8.7% (95% CI = 7.1% to 10.8%), respectively. CONCLUSIONS: Individuals with CRCs arising in the context of FCCTX do not experience the same improved DFS and overall survival of those with LS, and that difference may be relevant in management decisions.
  • Item
    No Preview Available
    Ability of known susceptibility SNPs to predict colorectal cancer risk for persons with and without a family history
    Jenkins, MA ; Win, AK ; Dowty, JG ; MacInnis, RJ ; Makalic, E ; Schmidt, DF ; Dite, GS ; Kapuscinski, M ; Clendenning, M ; Rosty, C ; Winship, IM ; Emery, JD ; Saya, S ; Macrae, FA ; Ahnen, DJ ; Duggan, D ; Figueiredo, JC ; Lindor, NM ; Haile, RW ; Potter, JD ; Cotterchio, M ; Gallinger, S ; Newcomb, PA ; Buchanan, DD ; Casey, G ; Hopper, JL (SPRINGER, 2019-10)
    Before SNP-based risk can be incorporated in colorectal cancer (CRC) screening, the ability of these SNPs to estimate CRC risk for persons with and without a family history of CRC, and the screening implications need to be determined. We estimated the association with CRC of a 45 SNP-based risk using 1181 cases and 999 controls, and its correlation with CRC risk predicted from detailed family history. We estimated the predicted change in the distribution across predefined risk categories, and implications for recommended screening commencement age, from adding SNP-based risk to family history. The inter-quintile risk ratio for colorectal cancer risk of the SNP-based risk was 3.28 (95% CI 2.54-4.22). SNP-based and family history-based risks were not correlated (r = 0.02). For persons with no first-degree relatives with CRC, screening could commence 4 years earlier for women (5 years for men) in the highest quintile of SNP-based risk. For persons with two first-degree relatives with CRC, screening could commence 16 years earlier for men and women in the highest quintile, and 7 years earlier for the lowest quintile. This 45 SNP panel in conjunction with family history, can identify people who could benefit from earlier screening. Risk reclassification by 45 SNPs could inform targeted screening for CRC prevention, particularly in clinical genetics settings when mutations in high-risk genes cannot be identified. Yet to be determined is cost-effectiveness, resources requirements, community, patient and clinician acceptance, and feasibility with potentially ethical, legal and insurance implications.
  • Item
    No Preview Available
    Early-life exposure to sibling modifies the relationship between CD14 polymorphisms and allergic sensitization
    Lau, MYZ ; Dharmage, SC ; Burgess, JA ; Win, AK ; Lowe, AJ ; Lodge, CJ ; Perret, J ; Hui, J ; Thomas, PS ; Giles, G ; Thompson, BR ; Abramson, MJ ; Walters, EH ; Matheson, MC ; Allen, KJ ; Benke, G ; Dowty, JG ; Erbas, B ; Feather, IH ; Frith, PA ; Gurrin, LC ; Hamilton, GS ; James, AL ; Jenkins, MA ; Johns, DP ; Markos, J ; Southey, MC ; Wood-Baker, R ; Barton, CA ; Bennett, CM ; Svanes, C ; Wjst, M ; Real, FG ; Russell, MA ; Axelrad, CJ ; Hill, DJ (WILEY, 2019-03)
    BACKGROUND: Markers of microbial exposure are thought to be associated with risk of allergic sensitization; however, the associations are inconsistent and may be related to gene-environment interactions. OBJECTIVE: To examine the relationship between polymorphisms in the CD14 gene and allergic sensitization and whether sibling exposure, as a marker of microbial exposure, modified this relationship. METHODS: We used data from the Tasmanian Longitudinal Health Study and the Melbourne Atopy Cohort Study. Two CD14 polymorphisms were genotyped. Allergic sensitization was defined by a positive response to a skin prick test. Sibling exposure was measured as cumulative exposure to siblings before age 6 months, 2 and 4 years. Logistic regression and multi-level mixed-effects logistic regression were used to examine the associations. Effect estimates across the cohorts were pooled using random-effects meta-analysis. RESULTS: CD14 SNPs were not individually associated with allergic sensitization in either cohort. In TAHS, cumulative sibling exposure before age 6 months, 2 and 4 years was each associated with a reduced risk of allergic sensitization at age 45 years. A similar effect was observed in MACS. Meta-analysis across the two cohorts showed consistent evidence of an interaction between cumulative sibling exposure before 6 months and the rs5744455-SNP (P = 0.001) but not with the rs2569190-SNP (P = 0.60). The pooled meta-analysis showed that the odds of sensitization with increasing cumulative exposure to sibling before 6 months of age was 20.9% smaller in those with the rs5744455-C-allele than the T-allele (OR = 0.83 vs 1.05, respectively). CONCLUSION AND CLINICAL RELEVANCE: Cumulative sibling exposure reduced the risk of sensitization from childhood to middle age in genetically susceptible individuals.
  • Item
    Thumbnail Image
    Cancer Risks for PMS2-Associated Lynch Syndrome (vol 29, pg 2961, 2018)
    ten Broeke, SW ; van der Klift, HM ; Tops, CMJ ; Aretz, S ; Bernstein, I ; Buchanan, DD ; de la Chapelle, A ; Capella, G ; Clendenning, M ; Engel, C ; Gallinger, S ; Garcia, EG ; Figueiredo, JC ; Haile, R ; Hampel, HL ; van Hest, L ; Hopper, JL ; Hoogerbrugge, N ; Doeberitz, MVK ; Le Marchand, L ; Letteboer, TGW ; Jenkins, MA ; Lindblom, A ; Lindor, NM ; Mensenkamp, AR ; Moller, P ; Newcomb, PA ; van Os, TAM ; Pearlman, R ; Pineda, M ; Rahner, N ; Redeker, EJW ; Olderode-Berends, MJW ; Rosty, C ; Schackert, HK ; Scott, R ; Senter, L ; Spruijt, L ; Steinke-Lange, V ; Suerink, M ; Thibodeau, S ; Vos, YJ ; Wagner, A ; Winship, I ; Hes, FJ ; Vasen, HFA ; Wijnen, JT ; Nielsen, M ; Win, AK (AMER SOC CLINICAL ONCOLOGY, 2019-03-20)
    This corrects the article "Cancer Risks for PMS2-Associated Lynch Syndrome" in volume 36 on page 2961.